Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community trial

Hdl Handle:
http://hdl.handle.net/10144/302225
Title:
Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community trial
Authors:
Daugla, D M; Gami, J P; Gamougam, K; Naibei, N; Mbainadji, L; Narbé, M; Toralta, J; Kodbesse, B; Ngadoua, C; Coldiron, M E; Fermon, F; Page, A-L; Djingarey, M H; Hugonnet, S; Harrison, O B; Rebbetts, L S; Tekletsion, Y; Watkins, E R; Hill, D; Caugant, D A; Chandramohan, D; Hassan-King, M; Manigart, O; Nascimento, M; Woukeu, A; Trotter, C; Stuart, J M; Maiden, M C J; Greenwood, B M
Journal:
Lancet
Abstract:
A serogroup A meningococcal polysaccharide-tetanus toxoid conjugate vaccine (PsA-TT, MenAfriVac) was licensed in India in 2009, and pre-qualified by WHO in 2010, on the basis of its safety and immunogenicity. This vaccine is now being deployed across the African meningitis belt. We studied the effect of PsA-TT on meningococcal meningitis and carriage in Chad during a serogroup A meningococcal meningitis epidemic.
Affiliation:
Centre de Support en Santé International (CSSI), N'Djamena, Chad.
Publisher:
Elsevier
Issue Date:
11-Sep-2013
URI:
http://hdl.handle.net/10144/302225
DOI:
10.1016/S0140-6736(13)61612-8
PubMed ID:
24035220
Language:
en
ISSN:
1474-547X
Appears in Collections:
Vaccination

Full metadata record

DC FieldValue Language
dc.contributor.authorDaugla, D Men_GB
dc.contributor.authorGami, J Pen_GB
dc.contributor.authorGamougam, Ken_GB
dc.contributor.authorNaibei, Nen_GB
dc.contributor.authorMbainadji, Len_GB
dc.contributor.authorNarbé, Men_GB
dc.contributor.authorToralta, Jen_GB
dc.contributor.authorKodbesse, Ben_GB
dc.contributor.authorNgadoua, Cen_GB
dc.contributor.authorColdiron, M Een_GB
dc.contributor.authorFermon, Fen_GB
dc.contributor.authorPage, A-Len_GB
dc.contributor.authorDjingarey, M Hen_GB
dc.contributor.authorHugonnet, Sen_GB
dc.contributor.authorHarrison, O Ben_GB
dc.contributor.authorRebbetts, L Sen_GB
dc.contributor.authorTekletsion, Yen_GB
dc.contributor.authorWatkins, E Ren_GB
dc.contributor.authorHill, Den_GB
dc.contributor.authorCaugant, D Aen_GB
dc.contributor.authorChandramohan, Den_GB
dc.contributor.authorHassan-King, Men_GB
dc.contributor.authorManigart, Oen_GB
dc.contributor.authorNascimento, Men_GB
dc.contributor.authorWoukeu, Aen_GB
dc.contributor.authorTrotter, Cen_GB
dc.contributor.authorStuart, J Men_GB
dc.contributor.authorMaiden, M C Jen_GB
dc.contributor.authorGreenwood, B Men_GB
dc.date.accessioned2013-09-24T20:47:45Z-
dc.date.available2013-09-24T20:47:45Z-
dc.date.issued2013-09-11-
dc.identifier.citationEffect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community trial. 2013: Lanceten_GB
dc.identifier.issn1474-547X-
dc.identifier.pmid24035220-
dc.identifier.doi10.1016/S0140-6736(13)61612-8-
dc.identifier.urihttp://hdl.handle.net/10144/302225-
dc.description.abstractA serogroup A meningococcal polysaccharide-tetanus toxoid conjugate vaccine (PsA-TT, MenAfriVac) was licensed in India in 2009, and pre-qualified by WHO in 2010, on the basis of its safety and immunogenicity. This vaccine is now being deployed across the African meningitis belt. We studied the effect of PsA-TT on meningococcal meningitis and carriage in Chad during a serogroup A meningococcal meningitis epidemic.en_GB
dc.languageENG-
dc.language.isoenen
dc.publisherElsevieren_GB
dc.rightsReproduced on this site with permission of Elsevier Ltd. Please see [url]http://www.thelancet.com/[/url] for further relevant comment.en_GB
dc.subjectMeningitisen_GB
dc.subjectVaccinationen_GB
dc.titleEffect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community trialen
dc.contributor.departmentCentre de Support en Santé International (CSSI), N'Djamena, Chad.en_GB
dc.identifier.journalLanceten_GB

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.